 The combination created a $23 billion diversified global pharmaceutical company with commercial reach across 100 countries.In June 2015, Actavis PLC officially changed its name to Allergan PLC.In December 2016, the company was accused of breaking competition law by “charging excessive and unfair prices” by the Competition and Markets Authority.